• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Isis appoints Dr. Jonas as executive vice president

Article

Carlsbad, CA-Jeffrey M. Jonas, MD, joined Isis Pharmaceuticals Inc. Feb. 1 as executive vice president. He will lead clinical development, preclinical development, regulatory affairs, quality assurance, and compliance at the company.

Carlsbad, CA-Jeffrey M. Jonas, MD, joined Isis Pharmaceuticals Inc. Feb. 1 as executive vice president. He will lead clinical development, preclinical development, regulatory affairs, quality assurance, and compliance at the company.

Dr. Jonas will be broadly responsible for the entire pipeline, both partnered and unpartnered, and contribute to portfolio management. In addition, he will be a principal representative of the company, interacting with investors and partners, working with Kate Corcoran, PhD, vice president, corporate development.

Prior to joining Isis, Dr. Jonas was chief medical officer and executive vice president at Forest Laboratories Inc., where he was responsible for clinical development, medical affairs, pharmacovigilence, and external scientific affairs.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.